fluticasone propionate/salmeterol combination DISKUS — Competitive Intelligence Brief

fluticasone propionate/salmeterol combination DISKUS (fluticasone propionate/salmeterol combination DISKUS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule

Target snapshot

fluticasone propionate/salmeterol combination DISKUS (fluticasone propionate/salmeterol combination DISKUS) — GlaxoSmithKline. Fluticasone propionate (an inhaled corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fluticasone propionate/salmeterol combination DISKUS TARGET	fluticasone propionate/salmeterol combination DISKUS	GlaxoSmithKline	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
RELVAR/BREO	RELVAR/BREO	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone 250/salmeterol 25	Fluticasone 250/salmeterol 25	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Symbicort Turbohaler without Turbo+	Symbicort Turbohaler without Turbo+	Istituto per la Ricerca e l'Innovazione Biomedica	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg	budesonide/formoterol Turbuhaler 320/9µg	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort 160/4.5 pMDI	Symbicort 160/4.5 pMDI	Allergy and Asthma Center of El Paso	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Fluticasone propionate/salmeterol combination	Fluticasone propionate/salmeterol combination	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

1. GlaxoSmithKline · 14 drugs in this class
2. Pearl Therapeutics, Inc. · 5 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. Research in Real-Life Ltd · 3 drugs in this class
5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
7. Johns Hopkins University · 1 drug in this class
8. National Jewish Health · 1 drug in this class
9. SkyePharma AG · 1 drug in this class
10. University Medical Center Groningen · 1 drug in this class